11. Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status. Issue 2 (4th August 2020) Authors: Alessi, Joao V; Ricciuti, Biagio; Jiménez-Aguilar, Elizabeth; Hong, Fangxin; Wei, Zihan; Nishino, Mizuki; Plodkowski, Andrew J; Sawan, Peter; Luo, Jia; Rizvi, Hira; Carter, Brett W; Heymach, John V; Altan, Mehmet; Hellmann, Matthew; Awad, Mark Journal: Journal for immunotherapy of cancer Issue: Volume 8:Issue 2(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
12. Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status. Issue 2 (4th August 2020) Authors: Alessi, Joao V; Ricciuti, Biagio; Jiménez-Aguilar, Elizabeth; Hong, Fangxin; Wei, Zihan; Nishino, Mizuki; Plodkowski, Andrew J; Sawan, Peter; Luo, Jia; Rizvi, Hira; Carter, Brett W; Heymach, John V; Altan, Mehmet; Hellmann, Matthew; Awad, Mark Journal: Journal for immunotherapy of cancer Issue: Volume 8:Issue 2(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
13. Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status. Issue 2 (4th August 2020) Authors: Alessi, Joao V; Ricciuti, Biagio; Jiménez-Aguilar, Elizabeth; Hong, Fangxin; Wei, Zihan; Nishino, Mizuki; Plodkowski, Andrew J; Sawan, Peter; Luo, Jia; Rizvi, Hira; Carter, Brett W; Heymach, John V; Altan, Mehmet; Hellmann, Matthew; Awad, Mark Journal: Journal for immunotherapy of cancer Issue: Volume 8:Issue 2(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
14. Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status. Issue 2 (4th August 2020) Authors: Alessi, Joao V; Ricciuti, Biagio; Jiménez-Aguilar, Elizabeth; Hong, Fangxin; Wei, Zihan; Nishino, Mizuki; Plodkowski, Andrew J; Sawan, Peter; Luo, Jia; Rizvi, Hira; Carter, Brett W; Heymach, John V; Altan, Mehmet; Hellmann, Matthew; Awad, Mark Journal: Journal for immunotherapy of cancer Issue: Volume 8:Issue 2(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
15. Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status. Issue 2 (4th August 2020) Authors: Alessi, Joao V; Ricciuti, Biagio; Jiménez-Aguilar, Elizabeth; Hong, Fangxin; Wei, Zihan; Nishino, Mizuki; Plodkowski, Andrew J; Sawan, Peter; Luo, Jia; Rizvi, Hira; Carter, Brett W; Heymach, John V; Altan, Mehmet; Hellmann, Matthew; Awad, Mark Journal: Journal for immunotherapy of cancer Issue: Volume 8:Issue 2(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
16. Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status. Issue 2 (4th August 2020) Authors: Alessi, Joao V; Ricciuti, Biagio; Jiménez-Aguilar, Elizabeth; Hong, Fangxin; Wei, Zihan; Nishino, Mizuki; Plodkowski, Andrew J; Sawan, Peter; Luo, Jia; Rizvi, Hira; Carter, Brett W; Heymach, John V; Altan, Mehmet; Hellmann, Matthew; Awad, Mark Journal: Journal for immunotherapy of cancer Issue: Volume 8:Issue 2(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
17. Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status. Issue 2 (4th August 2020) Authors: Alessi, Joao V; Ricciuti, Biagio; Jiménez-Aguilar, Elizabeth; Hong, Fangxin; Wei, Zihan; Nishino, Mizuki; Plodkowski, Andrew J; Sawan, Peter; Luo, Jia; Rizvi, Hira; Carter, Brett W; Heymach, John V; Altan, Mehmet; Hellmann, Matthew; Awad, Mark Journal: Journal for immunotherapy of cancer Issue: Volume 8:Issue 2(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
18. Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status. Issue 2 (4th August 2020) Authors: Alessi, Joao V; Ricciuti, Biagio; Jiménez-Aguilar, Elizabeth; Hong, Fangxin; Wei, Zihan; Nishino, Mizuki; Plodkowski, Andrew J; Sawan, Peter; Luo, Jia; Rizvi, Hira; Carter, Brett W; Heymach, John V; Altan, Mehmet; Hellmann, Matthew; Awad, Mark Journal: Journal for immunotherapy of cancer Issue: Volume 8:Issue 2(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗